Invesaro

Stocks Health care TOI

NASDAQ · Health care

Oncology Institute, Inc. (TOI)

Oncology Institute, Inc. brought in $587.2M of revenue over the twelve months to June 30, 2026, up 38.4% from a year earlier. It posted a net loss of $36.3M. In fiscal 2025 capital spending exceeded operating cash flow by $27.8M. At June 30, 2026 it held $41.1M in cash against $79.9M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.

Watch TOI in 60 seconds
Price
$5.13
0.00% on the day · August 3, 2026
52-week range $2.32 to $7.05
Market cap
$522.8M
Revenue (last 12 months)
$587.2M
+38.4% year on year
Net margin
-6.2%

What Oncology Institute, Inc. does

Oncology Institute, Inc. is registered with the SEC under industry code SIC 8011 (Services-Offices & Clinics of Doctors of Medicine). Its shares trade on NASDAQ under the ticker TOI.

Revenue and profit by year

Revenue
FY20: $187.5M $187.5M FY20FY21: $203M $203M FY21FY22: $252.5M $252.5M FY22FY23: $324.2M $324.2M FY23FY24: $393.4M $393.4M FY24FY25: $502.7M $502.7M FY25
Net income
FY20: -$14.3M -$14.3M FY20FY21: -$10.9M -$10.9M FY21FY22: $152K $152K FY22FY23: -$83.1M -$83.1M FY23FY24: -$64.7M -$64.7M FY24FY25: -$60.6M -$60.6M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$502.7M-$36.1M-$60.6M-$0.54-$27.8M
2024$393.4M-$60.1M-$64.7M-$0.71-$30.3M
2023$324.2M-$77M-$83.1M-$0.92-$40.9M
2022$252.5M-$82M$152K-$0.21-$67.3M
2021$203M-$45.9M-$10.9M-$0.16-$35.5M
2020$187.5M-$8.2M-$14.3M-$0.24-$686K

Full financial statements: income, balance sheet and cash flow

Next report expected around November 12, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 13, 2025. Not a date the company has announced. See the report calendar

Where TOI ranks in Health care

Revenue$502.7M
#204 of 742 in Health care · Top 27%
Revenue growth+27.8%
#143 of 529 in Health care · Top 27%
Net margin-12.1%
#294 of 541 in Health care · Bottom 46%
Free cash flow margin-5.5%
#280 of 488 in Health care · Bottom 43%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Oncology Institute, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 2, 2026
  2. August 21, 2026
  3. August 6, 2026
    Quarterly report 10-Q · period to June 30, 2026Revenue rose 35% to $161.3M versus the same quarter last year; diluted EPS -$0.08 versus -$0.15.
  4. August 6, 2026
  5. August 3, 2026
  6. July 7, 2026
  7. June 18, 2026
  8. May 22, 2026
  9. May 15, 2026
  10. May 7, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 24, 2026. Insider transactions on SEC

Insider trades

What the people running Oncology Institute, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders bought $78.5K and sold $1.9M worth of shares in the last 90 days. All of the selling was pre-planned under Rule 10b5-1 trading plans.

Bought (open market)
$78.5K
last 90 days
Sold
$1.9M
last 90 days
Net sold
286,853
$1.9M
DateInsiderWhatSharesPriceValueFiling
August 21, 2026 Hively BradDirector Soldpre-planned (10b5-1) 298,853 $6.51 $1.9M Form 4
August 14, 2026 Chernett Jorey10% owner Bought 12,000 $6.54 $78.5K Form 4
July 27, 2026 Johnson Karen MarieDirector Received as pay 31,124 - - Form 4
July 27, 2026 Hively BradDirector Received as pay 27,108 - - Form 4
July 27, 2026 Tzoumakas Kimberly JoDirector Received as pay 29,116 - - Form 4
July 27, 2026 Stolper MarkDirector Received as pay 31,124 - - Form 4
July 27, 2026 Pacala Mark LDirector Received as pay 30,120 - - Form 4
July 27, 2026 McGeorge AnneDirector Received as pay 41,165 - - Form 4
July 27, 2026 Kaushal MohitDirector Received as pay 33,133 - - Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns TOI

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

HolderOf classSharesFiled
Chernett Jorey13G, passive 10.2% 10,115,944 March 16, 2026

Latest filings below 5%: M33 Growth I L.P. 4.94% (May 15, 2026); FOG Ventures Investments, LLC 0% (June 24, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

8 insiders reported holding 12,320,634 shares in total, about $63.2M at the last price.

HolderSharesAs of
Chernett Jorey10% owner 10,660,858 August 14, 2026
Hively BradDirector 411,976 August 21, 2026
McGeorge AnneDirector 332,535 July 27, 2026
Johnson Karen MarieDirector 319,410 July 27, 2026
Pacala Mark LDirector 286,881 July 27, 2026
Kaushal MohitDirector 205,716 July 27, 2026
Stolper MarkDirector 56,957 July 27, 2026
Tzoumakas Kimberly JoDirector 46,301 July 27, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about TOI

What does Oncology Institute, Inc. do?

Oncology Institute, Inc. is registered with the SEC under industry code SIC 8011 (Services-Offices & Clinics of Doctors of Medicine). Its shares trade on NASDAQ under the ticker TOI.

Is Oncology Institute, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $36.3M on revenue of $587.2M.

How much revenue does Oncology Institute, Inc. make?

Over the twelve months to June 30, 2026 Oncology Institute, Inc. reported revenue of $587.2M. That is 38.4% more than a year earlier.

When did Oncology Institute, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the executive or director change from September 2, 2026.

Similar companies

Compare TOI with

Compare TOI with any company

Follow TOI

Get an email when Oncology Institute, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow TOI: get an email when it files

Where the numbers come from

Financial figures are the values Oncology Institute, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.